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Abstract 
Background: Malaria is a neglected tropical parasitic disease affecting billons of people around the globe. Though 
the number of cases and deaths associated with malaria are decreasing in recent years, it is the most deadly disease in 
the world. This study aimed at investigating the in vivo antimalarial activities of some 2,3-disubstituted-4(3H)-quina-
zolinone derivatives.
Results: The in vivo antimalarial activities of the test compounds (6–9 and 11–13) were investigated using the 4-day 
suppressive standard test in mice infected with chloroquine-sensitive Plasmodium berghei ANKA strain. The tested 
compounds showed significant antimalarial activities with mean percentage suppression of 43.71–72.86 % which is 
significantly higher than the negative control group (p < 0.05). Compounds 12 and 13 displayed better antimalarial 
activities from the group with mean percentage suppression of 67.60 and 72.86 % respectively.
Conclusion: The tested compounds showed significant in vivo antimalarial activities in mice infected with P. berghi 
ANKA strain. Thus, 3-aryl-2-(substitutedstyryl)-4(3H)-quinazolinones represent a possible scaffold for the development 
of antimalarial agents.
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Background
Malaria is a neglected tropical parasitic disease caused 
by a Plasmodian protozoan species [1]. It is transmit-
ted by the bite of female Anopheles mosquito through 
injection of sporozoites at the time of blood suck [2]. In 
2012, there were an estimated 3.4 billion people at risk 
of malaria, of whom 1.2 billion are at high risk. Children, 
pregnant women, HIV patients and travelers to sub-
Saharan African countries are at increased risk of severe 
malaria, if infected with P. falciparum [3]. The global 
number of malaria cases and deaths were estimated to 
have decreased since 2005 due to the expansion of access 
to rapid diagnostic tests, use of long-lasting insecticidal 
nets (136 million in 2013), quality assured artemisinin 
combination therapy (ACT) (331 million courses were 
produced in 2012) and increased funding for malaria 
control programs (US$ 2.5 billion in 2012) [4, 5].
Artemisinins and ACT with fixed dose combinations are 
the first-line treatment for falciparum malaria in almost all 
regions where malaria is endemic [6, 7] due to the emer-
gence of resistance P. falciparum strains to the older drugs 
[8–10]. Although artemisinins are potent and rapidly act-
ing antimalarial drugs, their widespread use for treating 
patients with P. falciparum malaria raises the question of 
emerging drug resistance [11]. Research findings revealed 
that treatment failures to artesunate-amodiaquine (AS-AQ) 
and artemether-lumefantrine (ALU) has been observed in 
different parts of the globe [12, 13]. In addition, artemisinin 
resistance has already emerged along the Thai-Cambodian 
border [14, 15]. Taking this into account, an aggressive and 
ambitious global effort is being made to discover new effec-
tive drugs for the treatment of malaria [16, 17].
The quinazoline nucleus, a basic unit found in various 
naturally occurring bioactive alkaloids, have continued to 
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attract interest due to their diverse pharmacological activ-
ities [18–21]. Different reports revealed that a wide num-
ber of quinazolinone derivatives demonstrated promising 
antimalarial activities [20, 22]. Recently, our group has 
synthesized and tested the antileishmanial activities of 
some 2,3-disubstituted-4(3H)-quinazolinone derivatives 
[23]. The aim of the present study was to evaluate the 
in  vivo antimalarial activities of these compounds (6–9 
and 11–13) using Swiss albino mice infected with chloro-
quine-sensitive P. berghei ANKA strain. In addition, oral 




Absolute ethanol, absolute methanol, distilled water, 
iodine, Giemsa stain, Tween 80, 1  % gum acacia were 
used in the study.
Experimental animals and test strains
Swiss albino male mice (age 6–8  weeks and weight 
20–32 g) bred and maintained under standard conditions 
(temperature of 22 ± 3 °C, relative humidity of 40–50 % 
and 12  h light/12  h dark cycle), with food and water 
ad libitum in the animal house of Biomedical Laboratory, 
Department of Biology, Faculty of Sciences, Addis Ababa 
University (AAU). They were acclimatized for one week 
for the experimental conditions.
Chloroquine-sensitive P. berghei ANKA strain used to 
infect the mice for a 4-day suppressive test was obtained 
from Biomedical Laboratory, Department of Biology, 
Faculty of Sciences, AAU. The parasite was maintained 
by serial passage of blood from infected mice to non-
infected ones on weekly basis.
Reference drugs
For the in vivo antimalarial activity testing, chloroquine 
phosphate (EPHARM, Addis Ababa, Ethiopia) was used 
as a reference drug.
In vivo antimalarial activity test
Parasite inoculation
Swiss albino mice previously infected with P. berghei and 
having parasitemia level of 20–30 % were used as donors. 
The donor mice was then sacrificed by decapitation and 
blood was collected by cardiac puncture into heparinized 
vacutainer tube containing 0.5  % trisodium citrate. The 
blood was then diluted with physiological saline based on 
parasitemia level of the donor mice and the red blood cell 
(RBC) count of normal mice, in such a way that 1 ml of 
blood contains 5 × 107 infected RBCs. Each mouse was 
given 0.2  ml of diluted blood intrapreritoneally, which 
contained 1 × 107 P. berghei infected RBCs [24].
Drugs used
Both chloroquine phosphate and the test compounds (6–
9 and 11–13) were dissolved in 70 % Tween 80 and 30 % 
ethanol. These solution were further diluted tenfold with 
distilled water to result in stock solutions containing 7 % 
Tween 80 and 3 % ethanol.
Grouping and dosing of animals
For the antimalarial evaluations of the target compounds, 
infected mice were randomly divided into nine groups of 
five mice per cage. Group 1 served as a negative control 
and group 2 served as a positive control. A vehicle con-
taining a solution of 7 % Tween 80, 3 % ethanol and 90 % 
distilled water (2  ml/100  g) and chloroquine phosphate 
25  mg/kg (48.46  µmol/kg) was administered orally to 
group 1 and 2 respectively. The remaining groups (group 
3–9) were treated with equimolar amounts (48.46 µmol/
kg) of the synthesized compounds through oral route for 
four consecutive days [25].
For the oral acute toxicity studies of each compound (12 
and 13), 36 male Swiss albino mice (approximately 20  g 
each) were randomly assigned to six groups (containing 
six mice per group). Group 1–5 were treated with each 
compound suspended in a vehicle containing 1  % gum 
acacia at a dose of 10, 50, 100, 200 and 300 mg/kg, respec-
tively. The sixth group received vehicle containing 1  % 
gum acacia (served as a negative control group) at a maxi-
mum dose of 1 ml/100 g of body weight by oral route [23].
The standard 4‑day suppressive test
The 4-day standard suppressive test was used to evaluate 
the in  vivo antimalarial activities of the test compounds 
using P. berghei infected mice [26]. Infected mice were 
randomly divided into their respective group as described 
under grouping and dosing. Treatment was started 2  h 
after mice had been inoculated with the parasite and con-
tinued for four consecutive days. Twenty-four hours after 
the last treatment (5th day), blood smears were taken from 
the tail of all mice, air dried, fixed with absolute methanol 
and stained with 6  % Giemsa stain. The parasitemia and 
percentage inhibition were then determined microscopi-
cally by counting four fields of approximately 100 eryth-
rocytes per field. The efficacies of compounds were finally 
assessed by comparison of blood parasitemia and mouse 
survival time in treated and untreated control mice [27].
Parasitemia measurement
Thin blood smears were made from the tail of each 
mouse on the 5th day. The smears were applied on 
microscope slides (76  ×  26  mm) (Menzel-Glaser, Ger-
many), fixed with absolute methanol and stained with 
10 % Giemsa stain at pH 7.2 for 15 min. The stained slides 
were washed gently using distilled water and air dried at 
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room temperature. Two stained slides for each mouse 
were examined under Olympus microscope (CHK2-F-
GS, Taiwan) with an oil immersion nose piece of 100× 
magnification. Four different fields on each slide were 
examined to calculate the average parasitemia as shown 
below [28].
Finally, percentage parasitemia suppression of the syn-
thesized were compared with respect to the controls and 




Number of parasitized RBC
Total number of RBC
× 100
is commonly used for antimalarial screening. In this 
method, determination of percentage inhibition of para-
sitemia is the most reliable parameter. The mean para-
sitemia level ≤90  % relative to that of placebo-treated 
control animals usually indicates that the test com-
pound is active in standard screening studies [33]. In 
this study, the standard 4-day suppressive test was used 
to evaluate the antimalarial activities of the synthesized 
compounds on chloroquine-sensitive P. berghei infected 
mice. Equimolar amounts (48.46  µmol/kg) of the syn-
thesized compounds and the standard drugs were 
administered through the oral route. The percent sup-
pression, percent parasitaemia, and mean survival time 
of the mice treated with the synthesized compounds 
Percentage suppression =
Mean parasitemia of negative control −Mean parasitemia of treated group
Mean parasitemia of negative control group
×100
In vivo acute toxicity test
The oral acute toxicities of the test compounds (12 and 
13) with promising antimalarial activities were investi-
gated in a dose of 10, 50, 100, 200 and 300 mg/kg. Ani-
mals were observed for gross body changes such as loss 
of appetite, hair erection, lacrimation, convulsions, sali-
vation, diarrhea, mortality and other signs of overt toxic-
ity [23].
Ethical clearance
The care and handling of the experimental animals was 
according to international guideline for use and main-
tenance of experimental animals [30] and Addis Ababa 
University, School of Pharmacy Ethics committee 
approved the protocol.
Statistical analysis
Results of the study were expressed as mean ± standard 
deviation and statistical significance for suppressive test 
was determined by one-way ANOVA using Origin 6.0 
software. Data on survival time, percentage parasitemia 
and percentage suppression was analyzed using Micro-
soft office excel 2007. All data was analyzed at 95 % con-
fidence interval.
Results and discussion
In vivo antimalarial activity results
The in vivo model was employed for this study because 
it takes into account the possible pro-drug effects and 
possible involvements of immune system in eradica-
tion of infection [31]. P. berghei ANKA stain was used in 
the prediction of treatment outcomes [32] and hence it 
was an appropriate parasite for the study. The standard 
4-day suppressive test, which mainly evaluates the anti-
malarial activity of candidate drugs on early infections, 
were compared against the control groups, as shown in 
Table 1.
The percentage parasitemia determined for all test 
compounds were significantly low relative to the nega-
tive control (p < 0.05), showing that the compounds are 
active. This significant antimalarial activity of the target 
compounds was also in agreement with that of the activ-
ity of 4(3H)-quinazolinone derivatives on the same para-
site strain [34]. The test compounds, 6, 7, 11, 12, and 13 
displayed mean percentage suppression of greater than 
50  %. On the other hand, compounds 8 and 9 had less 
than 50  % mean percent suppression compared to the 
untreated group (Table 1).
Compound 13 was the most active of the tested com-
pounds with mean percentage suppression of 72.86 %. 
The mean parasitemia level in mice treated with 13 
(17.71  ±  0.45) was found to be approximately four 
times lower than the negative control (65.25  ±  0.73), 
showing the compound has greatly reduced the para-
site load. This significant activity was further supported 
by better mean survival time (9.2 ± 0.43) of mice com-
pared with other test compounds but less than those of 
positive control (chloroquine-treated) group that did 
not show any death during the experimental period. 
Compound 12 displayed the next significant (p < 0.05) 
antimalarial activity with percentage suppression of 
67.60 % that is further confirmed by mean survival time 
(8.3 ± 0.55) (Table 1). The highest suppression effect of 
12 and 13 may be attributed to the presence of polar 
groups [hydroxyl group (–OH) in both 12 and 13, 
methoxy group (–OCH3) in 13] at 2-styryl moiety that 
may interact through hydrogen bonding with the active 
site.
The remaining compounds; 6, 7 and 11 demonstrated 
moderate antimalarial activities with mean percentage 
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Table 1 Data for antimalarial activity testing of the synthesized compounds (48.46 µmol/kg)
Test 
compound













































18.73 17.71 ± 0.45 72.86 9.2 ± 0.43
NCa – 65.25 ± 0.73 0.0 6.3 ± 0.86
CQ 25 0.0 100 ND
NC negative control, CQ chloroquine phosphate, ND no death
a Values are Mean ± SD, P < 0.05
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suppression of 55.41, 56.34 and 53.58 % respectively. These 
compounds possess electron withdrawing group at para 
position of 2-styryl group, which may increase the likelihood 
of strong hydrophobic interaction between the compounds 
and the active sites. However, they displayed relatively lower 
antimalarial activities as compared to compound 12 and 13.
Acute toxicity results
The acute toxicity study indicated that compounds 12 
and 13 caused no mortality in all doses (50, 100, 200 
and 300  mg/kg) within the first 24  h as well as for the 
following 14 days. Physical and behavioral observations 
of the experimental mice also revealed no visible signs 
of overt toxicity. Thus, compound 12 and 13 showed 
no inherent acute toxicity signs at a maximum dose of 
300 mg/kg.
Conclusions
The antimalarial activities of some 3-aryl-
2-(substitutedstyryl)-4(3H)-quinazolinone derivatives 
were tested. All the tested compounds showed signifi-
cant antimalarial activities as compared to the negative 
control group (p  <  0.05). Better antimalarial activities 
were observed for compound 12 and 13 with mean 
percentage suppression of 72.86 and 67.60  % respec-
tively. Thus, 2,3-disubstituted-4(3H)-quinazolinines 
containing an aromatic substitution at 3-position and 
substitutedstyryl moiety at 2-position represent a pos-
sible scaffold for the development of new antimalarial 
agents.
Abbreviations
ACT: artemisinins combination therapy; AS: artesunate; AQ: amodiaquine; A: 
artemether; LU: lumefantrine; RBC: red blood cells; AAU: Addis Ababa Univer-
sity; EPHARM: Ethiopian Pharmaceuticals manufacturer.
Authors’ contributions
YSB conducted the actual study and the statistical analysis. YSB, AAB and AH 
were involved in developing the idea and designing of the study. YSB and 
AH were also involved in the write up of the manuscript. All authors read and 
approved the final manuscript.
Author details
1 Department of Chemistry, Natural and Computational Sciences College, 
Debre Markos University, P.O. Box 269, Debre Markos, Ethiopia. 2 Department 
of Pharmaceutical Chemistry, Alexandria University, Alexandria 21215, Egypt. 
3 Department of Pharmaceutical Chemistry and Pharmacognosy, School 
of Pharmacy, Addis Ababa University, P.O. Box 1176, Addis Ababa, Ethiopia. 
Acknowledgements
Authors are thankful to Prof. Alemtsehay Mekonnen for permitting us to carry 
out the antimalarial activity test at the Biomedical Laboratory in the Depart-
ment of Biology, Faculty of Science, AAU.
Competing interests
The authors declare that they have no competing interests.
Received: 22 May 2015   Accepted: 14 October 2015
References
 1. Greenwood B, Mutabingwa T. Malaria in 2002. Nature. 2002;415:670–2.
 2. Mons B, Janse CJ, Boorsma EG, Van Der Kaay HJ. Synchronized eryth-
rocytic schizogony and gametocytogenesis of Plasmodium berghei 
in vivo and in vitro. Parasitol. 1985;91:423–30.
 3. Bellanger AP, Faucher JF, Robedat P, Schmitt A, Millon L, Hoen B. Malaria 
outbreak in French troops returning from Côte d’ Ivoire. Scand J Infect Dis. 
2011;43:230–3.
 4. WHO. The world malaria report from WHO global malaria program. 
Geneva: World Health Organization; 2010.
 5. WHO. The world malaria report from WHO global malaria program. 
Geneva: World Health Organization; 2013.
 6. Smithuis F, Kyaw MK, Phe O, Aye KH, Htet L, Barends M, Lindegardh 
N, Singtoroj T, Ashley E, Lwin S, Stepniewska K, White NJ. Efficacy and 
effectiveness of dihydroartemisinin-piperaquine versus artesunate-
mefloquine in falciparum malaria: an open-label randomized comparison. 
Lancet. 2006;367:2075–85.
 7. Alker AP, Lim P, Sem R, Shah NK, Yi P, Bouth DM, Tsuyuoka R, Maguire 
JD, Fandeur T, Ariey F, Wongsrichanalai C, Meshnick SR. Pfmdr1 and 
in vivo resistance to artesunate-mefloquine in falciparum malaria on the 
Cambodian-Thai border. Am J Trop Med Hyg. 2007;76:641–7.
 8. Rijken MJ, Boel ME, Russell B, Imwong M, Leimanis ML, Phyo AP, Muehlen-
bachs A, Lindegardh N, McGready R, Rénia L, Snounou G, Singhasivanon 
P, Nosten F. Chloroquine resistant vivax malaria in a pregnant woman on 
the western border of Thailand. Malaria J. 2011;10:113.
 9. White NJ. How antimalarial drug resistance affect post-treatment prophy-
laxis. Malaria J. 2008;7:9.
 10. Musset L, Bouchaud O, Matheron S, Massias L, Le Bras J. Clinical 
atovaquone-proguanil resistance of Plasmodium falciparum associ-
ated with cytochrome b codon 268 mutations. Microbes Infect. 
2006;8:2599–604.
 11. Denis MB, Tsuyuoka R, Poravuth Y, Narann TS, Seila S, Lim C, Incardona S, Lim 
P, Sem R, Socheat D, Chiristophel EM, Ringwald P. Surveillance of the efficacy 
of artesunate and mefloquine combination for the treatment of uncompli-
cated falciparum malaria in Cambodia. Trop Med Int Health. 2006;11:1360–6.
 12. Hasugian AR, Purba HLE, Kenangalem E, Wuwung RM, Ebsworth EP, 
Maristela R, Penttinen PMP, Laihad F, Anstey NM, Tjitra E, Price RN. 
Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: supe-
rior efficacy and post-treatment prophylaxis against multidrug-resistant P. 
falciparum and P. vivax malaria. Clin Infect Dis. 2007;44:1067–74.
 13. Dokomajilar C, Nsobya SL, Greenhouse B, Rosenthal PJ, Dorsey G. Selec-
tion of Plasmodium falciparum pfmdr1 alleles following therapy with 
artemether-lumefantrine in an area of Uganda where malaria is highly 
endemic. Antimicrob Agents Chemother. 2006;50:1893–5.
 14. Vijaykadga S, Rojanawatsirivej C, Cholpol S, Phoungduen D, Nakavej A, 
Wongsrichanalai C. In vivo sensitivity monitoring of mefloquine mono-
therapy and artesunate- mefloquine combinations for the treatment 
of uncomplicated falciparum malaria in Thailand in 2003. Trop Med Int 
Health. 2006;11:211–9.
 15. Noedl H, Socheat D, Satimai W. Artemisinin-resistant malaria in Asia. N 
Engl J Med. 2009;361:540–1.
 16. Olliaro P, Wells TN. The global portfolio of new antimalarial medicines 
under development. Clin Pharmacol Ther. 2009;85:584–95.
 17. Franklin BS, Ishizaka ST, Lamphier M, Gusovsky F, Hansen H, Rose J, Zheng 
W, Ataíde MA, de Oliveira RB, Golenbock DT, Gazzinelli RT. Therapeutical 
targeting of nucleic acid-sensing Toll-like receptors prevents experimen-
tal cerebral malaria. Proc Natl Acad Sci USA. 2011;108:3689–94.
 18. Shivananda MK, Holla BS. Antifungal activity studies of some quina-
zolinone derivatives. J Chem Pharm Res. 2011;3:83–6.
 19. Kumar A, Sharma P, Kumari P, Kalal BL. Exploration of antimicrobial and 
antioxidant potential of newly synthesized 2,3-disubstituted quinazoline-
4(3H)-ones. Bioorg Med Chem Lett. 2011;21:4353–7.
 20. Kabri Y, Azas N, Dumetre A, Hutter S, Laget M, Verhaeghe P, Gellis A, 
Vanelle P. Original quinazoline derivatives displaying antiplasmodial 
properties. Eur J Med Chem. 2010;45:616–22.
 21. Arfan M, Khan R, Khan MA, Anjum S, Choudhary MI, Ahmad M. Synthesis 
and antileishmanial and antimicrobial activities of some 2,3-disubstituted 
3H-quinazolin-4-ones. J Enzyme Inhib Med Chem. 2010;25:451–558.
 22. Zhu S, Zhang Q, Gudise C, Wei L, Smith E, Zeng Y. Synthesis and biological 
evaluation of febrifugine analogues as potential antimalarial agents. 
Bioorg Med Chem. 2009;17:4496–502.
Page 6 of 6Birhan et al. BMC Res Notes  (2015) 8:589 
 23. Birhan YS, Bekhit AA, Hymete A. Synthesis and antileishmanial evaluation 
of some 2,3-disubstituted-4(3H)-quinazolinone derivatives. Org Med 
Chem Lett. 2014;4:10.
 24. Ishih A, Miyase T, Terada M. Comparison of antimalarial activity of the 
alkaloidal fraction of Hydrangea macrophylla var. Otaksa leaves with the 
hot-water extract in ICR mice infected with Plasmodium yoelii 17 XL. 
Phytother Res. 2003;17:633–9.
 25. Dominguez JN, Leon C, Rodrigues J, Neira GD, Gut J, Rosenthal PJ. Syn-
thesis of chlorovinyl sulfones as structural analogs of chalcones and their 
antiplasmodial activities. Eur J Med Chem. 2009;44:1457–62.
 26. Peters W, Portus JH, Robinson BL. The four-day suppressive in vivo anti-
malarial test. Ann Trop Med Parasitol. 1975;69:155–71.
 27. Trager W, Jensen JB. Human malaria parasites in continuous culture. Sci-
ence. 1976;193:673–5.
 28. Hilou A, Nacoulma G, Guiguemde TR. In vivo antimalarial activities of 
extracts from Amaranthus spinosus and Boerhaavia erecta in mice. J 
Ethnopahrmacol. 2006;103:236–40.
 29. Kalra BS, Chawla S, Gupta P, Valecha N. Screening of antimalarial drugs. 
Ind J Pharmacol. 2006;38:5–12.
 30. The Organization of Economic Co-operation and Development (OECD). 
The OECD guidelines for testing of chemicals 420, acute oral toxicity. 
France; 2001.
 31. Waako PJ, Gumede B, Smith P, Folb PI. The in vitro and in vivo antimalarial 
activity of Cardiospermum haicacabum and Momordica foetida. J Ethnop-
harmacol. 2005;99:137–43.
 32. Dikasso D, Mekonnen E, Debella A, Abebe D, Urga K, Mekonnen W, Mel-
aku D, Assefa A, Mekonnen Y. In vivo antimalarial activity of hydroalcoholic 
extracts from Asparagus africanus Lam. in mice infected with Plasmodium 
berghei. Ethiop J Health Dev. 2006;20:112–8.
 33. Peter IT, Anatoli VK. The current global malaria situation Malaria parasite biol-
ogy, pathogenesis and protection. Washington, DC: ASM press; 1998. p. 11–22.
 34. Zhu S, Wang J, Chandrashekar G, Smith E, Liu X, Zhang Y. Synthesis and 
Evaluation of 4-quinazolinone compounds as potential antimalarial 
agents. Eur J Med Chem. 2010;45:3864–9.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
